David Menter

David Menter is a Senior Professor at The University of Texas MD Anderson Cancer Center, where his research focuses on oncology, colorectal cancer biology, and molecular cancer pharmacology. His work investigates oncogenes, cancer cell pathology, and immunology, with recent breakthroughs including the ASCEND-CRC program for cancer evolution profiling and interception in colorectal cancer, as well as spatial multi-omics dissection of colorectal cancer micrometastasis. He has pioneered studies on targeting mitochondrial complex I to overcome adaptive chemotherapy resistance in advanced pancreatic cancer and leads clinical trials on TROP2 CAR-engineered NK cells combined with cetuximab for colorectal cancer with minimal residual disease. His recent publications appear in Cancer Cell, Cancer Research, and the Journal of Clinical Oncology, reflecting his contributions to cancer interception and immunotherapy.